After getting the crucial first-mover advantage with an FDA approval for a weight loss pill, Novo Nordisk looks to win the market before rival Lilly can arrive with its own oral option for obesity.
Novo Unveils Oral Wegovy in the US, With Out-of-Pocket Prices at $149 Per Month